✉ Email this page to a colleague
« Back to Dashboard
Icosabutate is an investigational drug.
There have been 5 clinical trials for Icosabutate. The most recent clinical trial was a Phase 1 trial, which was initiated on July 17th 2019.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Dyslipidemias. The leading clinical trial sponsors are Pronova BioPharma, NorthSea Therapeutics B.V., and [disabled in preview].
There are seven US patents protecting this investigational drug and one hundred and twenty-two international patents.
Recent Clinical Trials for Icosabutate
|A Phase 2b Study of Icosabutate in Fatty Liver Disease||NorthSea Therapeutics B.V.||Phase 2|
|A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval||NorthSea Therapeutics B.V.||Phase 1|
|Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects||Pronova BioPharma||Phase 1|
Top disease conditions for Icosabutate
Top clinical trial sponsors for Icosabutate
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Icosabutate||See Plans and Pricing||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||See Plans and Pricing|
|Icosabutate||See Plans and Pricing||Oral drug dosage forms having desired drug release profiles and uses thereof||Triastek, Inc. (Nanjing, CN)||See Plans and Pricing|
|Icosabutate||See Plans and Pricing||Compartmented pharmaceutical dosage forms||Triastek, Inc. (Nanjing, CN)||See Plans and Pricing|
|Icosabutate||See Plans and Pricing||Substituted fatty acids for treating non-alcoholic steatohepatitis||BASF AS (Oslo, NO)||See Plans and Pricing|
|Icosabutate||See Plans and Pricing||Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas||Pronova Biopharma Norge AS (Baerum, NO)||See Plans and Pricing|
|Icosabutate||See Plans and Pricing||Methods of preparing fatty acid derivatives||Pronova Biopharma Norge AS (Lysaker, NO)||See Plans and Pricing|
|Icosabutate||See Plans and Pricing||Methods of treatment using lipid compounds||PRONOVA BIOPHARMA NORGE AS (Lysaker, NO)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Icosabutate||Australia||AU2017261372||2036-05-05||See Plans and Pricing|
|Icosabutate||Canada||CA3023278||2036-05-05||See Plans and Pricing|
|Icosabutate||China||CN107847398||2036-05-05||See Plans and Pricing|
|Icosabutate||European Patent Office||EP3452003||2036-05-05||See Plans and Pricing|
|Icosabutate||Hong Kong||HK1249728||2036-05-05||See Plans and Pricing|
|Icosabutate||Japan||JP2019520866||2036-05-05||See Plans and Pricing|
|Icosabutate||Japan||JP6559912||2036-05-05||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|